Castle Biosciences (CSTL) Net Cash Flow (2018 - 2026)

Castle Biosciences has reported Net Cash Flow for 9 years, with the latest figure at -$1.6 million in Q2 2026.

• Quarterly Net Cash Flow rose 77.9% year-over-year to -$1.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$20.1 million (down 502.49% YoY) and the FY2025 annual result came in at -$3.0 million, down 114.28% from the prior year.
• Net Cash Flow improved to -$1.6 million in Q2 2026 per CSTL's latest filing, from -$53.0 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $31.2 million in Q4 2025 and troughed at -$139.0 million in Q3 2022.
• A 5-year average of -$14.9 million and a median of -$7.8 million in 2023 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2022 and 2024: Net Cash Flow slumped 2592.48% in 2022, then jumped 301.83% in 2024.
• Over 5 years, Net Cash Flow stood at -$11.2 million in 2022, then surged by 167.82% to $7.6 million in 2023, then surged by 224.89% to $24.8 million in 2024, then grew by 25.95% to $31.2 million in 2025, then plunged by 105.29% to -$1.6 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$1.6 million, -$53.0 million, and $31.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.